Slate Daily Feed22 Des 2022

Political Gabfest - Inciting Insurrection

This week, David Plotz, Emily Bazelon, and John Dickerson discuss the January 6th Committee’s findings and criminal referrals; the brewing water crisis in the West–with Washington Post reporter Josh Partlow; and the biggest stories of 2022.

Here are some notes and references from this week’s show:

Joshua Partlow for The Washington Post: “Officials Fear ‘Complete Doomsday Scenario’ For Drought-Stricken Colorado River”

Joshua Partlow for The Washington Post: “Disaster Scenarios Raise The Stakes For Colorado River Negotiations”

Joshua Partlow for The Washington Post: “‘Where There’s Bodies, There’s Treasure’: A Hunt As Lake Mead Shrinks”

Adam Liptak for The New York Times: “An ‘Imperial Supreme Court’ Asserts Its Power, Alarming Scholars”

Marin Cogan for Vox: “The Deadliest Road in America”

Here are this week’s chatters:

John: Gabfest Reads: How to Avoid Disastrous Presidents; Picking Presidents: How to Make the Most Consequential Decision in the World, by Gautam Mukunda

Emily: Mario Ariza and Miranda Green for Floodlight News, and David Folkenflik for NPR: “In The Southeast, Power Company Money Flows To News Sites That Attack Their Critics”

David: Li Cohen for CBS News: “Could Jack Have Fit On The Door With Rose In 'Titanic’? Director James Cameron Conducted A Study To Find Out ‘Once And For All.’”

Listener chatter from Sam Rutledge: Kaj Tallungs for Wikimedia Commons: data visualization showing the change in U.S. population demographics over time.

For this week’s Slate Plus bonus segment Emily, David, and John discuss Elon Musk’s tumultuous tenure at Twitter.

Tweet us your questions and chatters @SlateGabfest or email us at gabfest@slate.com. (Messages may be quoted by name unless the writer stipulates otherwise.)

Podcast production by Cheyna Roth.

Research by Bridgette Dunlap.

Hosted on Acast. See acast.com/privacy for more information.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(4958)

What Next - The Odyssey’s Neverending Journey Through the Discourse

Roiling like a wine-dark sea since the casting was announced, controversies surrounding Christopher Nolan’s “The Odyssey” didn’t stop with the film’s release. But what turned a summer blockbuster into...

3 Aug 27min

Amicus With Dahlia Lithwick | Law, justice, and the courts - By The People | Two Steps Forward, One Step Back

Long before the Supreme Court handed down the landmark Obergefell ruling on equal marriage in 2015, activists were canvassing door-to-door, courting any lawmaker who would listen, and losing at the lo...

1 Aug 45min

ICYMI - Women's Health Is Not Your Clickbait

Women’s health is being yassified online, from ill-advised marketing campaigns by companies trying to go viral to creators pushing anti-abortion agendas under the guise of “natural” birth control. It ...

1 Aug 39min

Slate Money - Too Situationally Aware to Fail

This week: Situational Awareness—an A.I.-forward hedge fund led by a former wunderkind and OpenAI employee—was tanking fast until a rival fund stepped in. Felix Salmon, Elizabeth Spiers, and Emily Pec...

1 Aug 54min

What Next - Bonus: Cory Booker on Blanche, Epstein, and 2028

As part of the Senate Judiciary Committee, Senator Cory Booker had questions for Todd Blanche—and made space for Jeffrey Epstein survivors. Guest: Cory Booker, US Senator for New Jersey, member of the...

31 Jul 6min

What Next: TBD | Tech, power, and the future - Can We Trust the Jobs Report?

The Bureau of Labor Statistics is a department for wonks, by wonks. But under the dual pressures of the changing nature of work—like the growing gig economy—and an administration that doesn’t accept b...

31 Jul 32min

Political Gabfest - Unhinged Obsession

This week, Emily Bazelon, John Dickerson, and David Plotz discuss the expanding Iran war and what it means for Trump that news of U.S. missile shortages is leaking from the inside, the blend of conspi...

30 Jul 50min

What Next - What the Hell is a Peptide?

On the heels of the success of GLP-1s like Ozempic, other peptide treatments are flooding the marketplace—and advertising spaces. But even as the Trump administration’s FDA discusses approving more tr...

30 Jul 26min